Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 41

1.

Predialysis systolic BP variability and outcomes in hemodialysis patients.

Shafi T, Sozio SM, Bandeen-Roche KJ, Ephraim PL, Luly JR, St Peter WL, McDermott A, Scialla JJ, Crews DC, Tangri N, Miskulin DC, Michels WM, Jaar BG, Herzog CA, Zager PG, Meyer KB, Wu AW, Boulware LE; DEcIDE Network Patient Outcomes in End Stage Renal Disease Study Investigators.

J Am Soc Nephrol. 2014 Apr;25(4):799-809. doi: 10.1681/ASN.2013060667. Epub 2014 Jan 2.

2.

Selective cell adhesion inhibitors: Barbituric acid based alpha4beta7--MAdCAM inhibitors.

Harriman GC, Brewer M, Bennett R, Kuhn C, Bazin M, Larosa G, Skerker P, Cochran N, Gallant D, Baxter D, Picarella D, Jaffee B, Luly JR, Briskin MJ.

Bioorg Med Chem Lett. 2008 Apr 1;18(7):2509-12. doi: 10.1016/j.bmcl.2007.07.068. Epub 2007 Aug 21.

PMID:
18331794
3.

Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure.

Radwan MH, Yan Y, Luly JR, Figenshau RS, Brandes SB, Bhayani SB, Bullock AD, Liefu Y, Andriole GL, Kibel AS.

Urology. 2007 Jun;69(6):1121-7.

PMID:
17572199
4.

Rapamycin analogs with reduced systemic exposure.

Wagner R, Mollison KW, Liu L, Henry CL, Rosenberg TA, Bamaung N, Tu N, Wiedeman PE, Or Y, Luly JR, Lane BC, Trevillyan J, Chen YW, Fey T, Hsieh G, Marsh K, Nuss M, Jacobson PB, Wilcox D, Carlson RP, Carter GW, Djuric SW.

Bioorg Med Chem Lett. 2005 Dec 1;15(23):5340-3. Epub 2005 Sep 26.

PMID:
16185865
5.

Synthesis and structure-activity relationship of 2-amino-3-heteroaryl-quinoxalines as non-peptide, small-molecule antagonists for interleukin-8 receptor.

Li JJ, Carson KG, Trivedi BK, Yue WS, Ye Q, Glynn RA, Miller SR, Connor DT, Roth BD, Luly JR, Low JE, Heilig DJ, Yang W, Qin S, Hunt S.

Bioorg Med Chem. 2003 Aug 15;11(17):3777-90.

PMID:
12901923
6.

A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects.

Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin CW, Elmore SW, Kym PR, Luly JR, Carter GW, Turner R, Tyree CM, Hu J, Elgort M, Rosen J, Miner JN.

Mol Endocrinol. 2003 May;17(5):860-9. Epub 2003 Feb 13.

PMID:
12586843
7.

Potent inhibition of NFAT activation and T cell cytokine production by novel low molecular weight pyrazole compounds.

Trevillyan JM, Chiou XG, Chen YW, Ballaron SJ, Sheets MP, Smith ML, Wiedeman PE, Warrior U, Wilkins J, Gubbins EJ, Gagne GD, Fagerland J, Carter GW, Luly JR, Mollison KW, Djuric SW.

J Biol Chem. 2001 Dec 21;276(51):48118-26. Epub 2001 Oct 9.

8.

Synthesis and characterization of non-steroidal ligands for the glucocorticoid receptor: selective quinoline derivatives with prednisolone-equivalent functional activity.

Coghlan MJ, Kym PR, Elmore SW, Wang AX, Luly JR, Wilcox D, Stashko M, Lin CW, Miner J, Tyree C, Nakane M, Jacobson P, Lane BC.

J Med Chem. 2001 Aug 30;44(18):2879-85.

PMID:
11520196
9.

3,5-Bis(trifluoromethyl)pyrazoles: a novel class of NFAT transcription factor regulator.

Djuric SW, BaMaung NY, Basha A, Liu H, Luly JR, Madar DJ, Sciotti RJ, Tu NP, Wagenaar FL, Wiedeman PE, Zhou X, Ballaron S, Bauch J, Chen YW, Chiou XG, Fey T, Gauvin D, Gubbins E, Hsieh GC, Marsh KC, Mollison KW, Pong M, Shaughnessy TK, Sheets MP, Smith M, Trevillyan JM, Warrior U, Wegner CD, Carter GW.

J Med Chem. 2000 Aug 10;43(16):2975-81.

PMID:
10956206
10.

Retention of immunosuppressant activity in an ascomycin analogue lacking a hydrogen-bonding interaction with FKBP12.

Wiedeman PE, Fesik SW, Petros AM, Nettesheim DG, Mollison KW, Lane BC, Or YS, Luly JR.

J Med Chem. 1999 Oct 21;42(21):4456-61.

PMID:
10543889
11.

Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin.

Burke SE, Lubbers NL, Chen YW, Hsieh GC, Mollison KW, Luly JR, Wegner CD.

J Cardiovasc Pharmacol. 1999 Jun;33(6):829-35.

PMID:
10367584
12.

A macrolactam inhibitor of T helper type 1 and T helper type 2 cytokine biosynthesis for topical treatment of inflammatory skin diseases.

Mollison KW, Fey TA, Gauvin DM, Kolano RM, Sheets MP, Smith ML, Pong M, Nikolaidis NM, Lane BC, Trevillyan JM, Cannon J, Marsh K, Carter GW, Or YS, Chen YW, Hsieh GC, Luly JR.

J Invest Dermatol. 1999 May;112(5):729-38.

13.

Discovery of ascomycin analogs with potent topical but weak systemic activity for treatment of inflammatory skin diseases.

Mollison KW, Fey TA, Gauvin DM, Sheets MP, Smith ML, Pong M, Krause R, Miller L, Or YS, Kawai M, Wagner R, Wiedeman PE, Clark RF, Gunawardana IW, Rhoades TA, Henry CL, Tu NP, BaMaung NY, Kopecka H, Liu L, Xie Q, Lane BC, Trevillyan JM, Marsh K, Luly JR, et al.

Curr Pharm Des. 1998 Oct;4(5):367-79. Review.

PMID:
10197049
14.

Synthesis and immunosuppressant activity of pyrazole carboxamides.

Wang AX, Xie Q, Lane B, Mollison KW, Hsieh GC, Marsh K, Sheets MP, Luly JR, Coghlan MJ.

Bioorg Med Chem Lett. 1998 Oct 6;8(19):2787-92.

PMID:
9873623
15.

Studies on an immunosuppressive macrolactam, ascomycin: synthesis of a C-33 hydroxyl derivative.

Kawai M, Gunawardana IW, Mollison KW, Hsieh GC, Lane BC, Luly JR.

Bioorg Med Chem Lett. 1998 Apr 21;8(8):935-8.

PMID:
9871515
16.

32-Ascomycinyloxyacetic acid derived immunosuppressants. Independence of immunophilin binding and immunosuppressive potency.

Wagner R, Rhoades TA, Or YS, Lane BC, Hsieh G, Mollison KW, Luly JR.

J Med Chem. 1998 May 21;41(11):1764-76.

PMID:
9599228
17.

Improved methods for transplanting split-heart neonatal cardiac grafts into the ear pinna of mice and rats.

Fey TA, Krause RA, Hsieh GC, Andrews JM, Bretheim PT, Morgan SJ, Luly JR, Mollison KW.

J Pharmacol Toxicol Methods. 1998 Feb;39(1):9-17.

PMID:
9596143
18.

Nephrotoxicity studies of the immunosuppressants tacrolimus (FK506) and ascomycin in rat models.

Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Cusick PK, Hsieh GC, Luly JR.

Toxicology. 1998 Feb 6;125(2-3):169-81.

PMID:
9570331
19.

Discovery of less nephrotoxic FK506 analogs and determining immunophilin dependence of immunosuppressant nephrotoxicity with a novel single-dose rat cisplatin potentiation assay.

Mollison KW, Fey TA, Krause RA, Andrews JM, Bretheim PT, Brandt JA, Kawai M, Wagner R, Hsieh GC, Luly JR.

J Pharmacol Exp Ther. 1997 Dec;283(3):1509-19.

PMID:
9400028
20.

Discovery of FK 506 analogues that are nontoxic to mouse pancreatic beta cells in vitro but show diabetogenic potential when administered to the rat.

Mollison KW, Andrews JM, Fey TA, Miller LN, Krause RA, Bretheim PT, Brandt JA, Wagner R, Lane BC, Hsieh GC, Luly JR.

Transplant Proc. 1996 Dec;28(6):3185-8. No abstract available.

PMID:
8962236
21.

Comparison of FK-506, rapamycin, ascomycin, and cyclosporine in mouse models of host-versus-graft disease and heterotopic heart transplantation.

Mollison KW, Fey TA, Krause RA, Thomas VA, Mehta AP, Luly JR.

Ann N Y Acad Sci. 1993 Jun 23;685:55-7. No abstract available.

PMID:
7689812
22.
23.

Evaluation of calcineurin's role in the immunosuppressive activity of FK 506, related macrolactams, and cyclosporine.

Lane BC, Miller LN, Kawai M, Or YS, Wiedeman P, Holzman TF, Luly JR.

Transplant Proc. 1993 Feb;25(1 Pt 1):644-6. No abstract available.

PMID:
7679829
24.

Structure-activity profiles of macrolactam immunosuppressant FK-506 analogues.

Kawai M, Lane BC, Hsieh GC, Mollison KW, Carter GW, Luly JR.

FEBS Lett. 1993 Jan 25;316(2):107-13.

25.

Effects of angiotensinase inhibitors on plasma protein binding and IC50 determinations of renin inhibitors.

Dayton BD, Stein HH, Cohen J, Baker WR, Boyd SA, Condon SL, Donner BG, Fung AK, Luly JR, Rosenberg SH, et al.

Clin Chem. 1992 Nov;38(11):2239-43.

26.

Conformation of two non-immunosuppressive FK506 analogs when bound to FKBP by isotope-filtered NMR.

Petros AM, Kawai M, Luly JR, Fesik SW.

FEBS Lett. 1992 Aug 24;308(3):309-14.

27.

Improvements in the minimum binding sequence of C5a: examination of His-67.

Or YS, Clark RF, Lane B, Mollison KW, Carter GW, Luly JR.

J Med Chem. 1992 Jan 24;35(2):402-6. No abstract available.

PMID:
1732557
28.

Structure-function studies in a series of carboxyl-terminal octapeptide analogues of anaphylatoxin C5a.

Kawai M, Quincy DA, Lane B, Mollison KW, Or YS, Luly JR, Carter GW.

J Med Chem. 1992 Jan 24;35(2):220-3.

PMID:
1732540
29.

NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding.

Petros AM, Gampe RT Jr, Gemmecker G, Neri P, Holzman TF, Edalji R, Hochlowski J, Jackson M, McAlpine J, Luly JR, et al.

J Med Chem. 1991 Sep;34(9):2925-8. No abstract available.

PMID:
1716684
30.

Identification and synthesis of a receptor binding site of human anaphylatoxin C5a.

Kawai M, Quincy DA, Lane B, Mollison KW, Luly JR, Carter GW.

J Med Chem. 1991 Jul;34(7):2068-71.

PMID:
2066977
31.

Isotope-edited NMR of cyclosporin A bound to cyclophilin: evidence for a trans 9,10 amide bond.

Fesik SW, Gampe RT Jr, Holzman TF, Egan DA, Edalji R, Luly JR, Simmer R, Helfrich R, Kishore V, Rich DH.

Science. 1990 Dec 7;250(4986):1406-9.

PMID:
2255910
32.

Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a structurally modified phenylalanine residue to impart proteolytic stability.

Plattner JJ, Marcotte PA, Kleinert HD, Stein HH, Greer J, Bolis G, Fung AK, Bopp BA, Luly JR, Sham HL, et al.

J Med Chem. 1988 Dec;31(12):2277-88.

PMID:
3143010
33.

Renin inhibitors. Dipeptide analogues of angiotensinogen utilizing a dihydroxyethylene transition-state mimic at the scissile bond to impart greater inhibitory potency.

Luly JR, BaMaung N, Soderquist J, Fung AK, Stein H, Kleinert HD, Marcotte PA, Egan DA, Bopp B, Merits I, et al.

J Med Chem. 1988 Dec;31(12):2264-76.

PMID:
3143009
34.

Isotope-edited proton NMR study on the structure of a pepsin/inhibitor complex.

Fesik SW, Luly JR, Erickson JW, Abad-Zapatero C.

Biochemistry. 1988 Nov 1;27(22):8297-301.

PMID:
3149502
35.

Effects of the renin inhibitor A-64662 in monkeys and rats with varying baseline plasma renin activity.

Kleinert HD, Martin D, Chekal MA, Kadam J, Luly JR, Plattner JJ, Perun TJ, Luther RR.

Hypertension. 1988 Jun;11(6 Pt 2):613-9.

PMID:
3292414
36.

Renin inhibitors. Improvements in the stability and biological activity of small peptides containing novel Leu-Val replacements.

Kleinert HD, Luly JR, Marcotte PA, Perun TJ, Plattner JJ, Stein H.

FEBS Lett. 1988 Mar 28;230(1-2):38-42.

37.

New inhibitors of human renin that contain novel Leu-Val replacements. Examination of the P1 site.

Luly JR, Bolis G, BaMaung N, Soderquist J, Dellaria JF, Stein H, Cohen J, Perun TJ, Greer J, Plattner JJ.

J Med Chem. 1988 Mar;31(3):532-9.

PMID:
3279206
38.

Optimization and in vivo evaluations of a series of small, potent, and specific renin inhibitors containing a novel Leu-Val replacement.

Dellaria JF, Maki RG, Bopp BA, Cohen J, Kleinert HD, Luly JR, Merits I, Plattner JJ, Stein HH.

J Med Chem. 1987 Nov;30(11):2137-44.

PMID:
3118024
39.

Amide proton exchange rates of a bound pepsin inhibitor determined by isotope-edited proton NMR experiments.

Fesik SW, Luly JR, Stein HH, BaMaung N.

Biochem Biophys Res Commun. 1987 Sep 30;147(3):892-8.

PMID:
2822045
40.

New inhibitors of human renin that contain novel Leu-Val replacements.

Luly JR, Yi N, Soderquist J, Stein H, Cohen J, Perun TJ, Plattner JJ.

J Med Chem. 1987 Sep;30(9):1609-16.

PMID:
3305946
41.

Modified peptides which display potent and specific inhibition of human renin.

Luly JR, Plattner JJ, Stein H, Yi N, Soderquist J, Marcotte PA, Kleinert HD, Perun TJ.

Biochem Biophys Res Commun. 1987 Feb 27;143(1):44-51.

PMID:
3548726

Supplemental Content

Support Center